<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ipratropium bromide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00332</strong>&#160; (APRD00537)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00332/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00332/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00332.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00332.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00332.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00332.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00332.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00332">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Ipratropium bromide monohydrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000208/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000208/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: OEXHQOGQTVQTAT-IPHBXJNRSA-N</li>
              <li>Monoisotopic Mass: 332.222568831</li>
              <li>Average Mass: 332.4571</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000208">DBSALT000208</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Aerovent</td><td>Teva</td></tr><tr><td>Apovent</td><td>Apotex Inc.</td></tr><tr><td>Atronase</td><td>Boehringer Ingelheim</td></tr><tr><td>Atrovent</td><td>Boehringer Ingelheim</td></tr><tr><td>AtroventHFA</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ipraxa</td><td>Ivax</td></tr><tr><td>Ipvent</td><td>Cipla Medpro</td></tr><tr><td>Rhinovent</td><td>Boehringer Ingelheim</td></tr><tr><td>Rinatec</td><td>Boehringer Ingelheim</td></tr><tr><td>Rinovagos</td><td>Valeas</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Combivent Inhalation Aerosol</td><td>Ipratropium Bromide + Salbutamol Sulfate</td></tr><tr><td>Combivent Inhalation Solution</td><td>Ipratropium Bromide + Salbutamol Sulfate</td></tr><tr><td>DuoNeb</td><td>Ipratropium bromide + Salbutamol</td></tr><tr><td>Duovent UDV</td><td>Fenoterol Hydrobromide + Ipratropium Bromide</td></tr><tr><td>Ratio-Ipra SAL UDV</td><td>Ipratropium Bromide + Salbutamol Sulfate</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/bronchodilator-agents">Bronchodilator Agents</a></li>
<li><a href="/mesh/muscarinic-antagonists">Muscarinic Antagonists</a></li>
<li><a href="/mesh/cholinergic-antagonists">Cholinergic Antagonists</a></li>
<li><a href="/mesh/antispasmodics">Antispasmodics</a></li></ul></td></tr><tr><th>CAS number</th><td>60205-81-4</td></tr><tr><th>Weight</th><td>Average: 412.361<br>Monoisotopic: 411.140906478</td></tr><tr><th>Chemical Formula</th><td>C<sub>20</sub>H<sub>30</sub>BrNO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>LHLMOSXCXGLMMN-VVQPYUEFSA-M</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C20H30NO3.BrH/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H/q+1;/p-1/t16-,17+,18+,19?,21+;</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1R,3R,5S,8R)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-8-ium bromide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenylacetic Acid Derivatives</td></tr><tr><th>Direct parent</th><td>Phenylacetic Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Tropanes; Beta Hydroxy Acids and Derivatives; Piperidines; Pyrrolidines; Carboxylic Acid Esters; Ethers; Enolates; Polyamines; Primary Alcohols</td></tr><tr><th>Substituents</th><td>beta-hydroxy acid; hydroxy acid; piperidine; pyrrolidine; carboxylic acid ester; carboxylic acid derivative; enolate; ether; primary alcohol; polyamine; organonitrogen compound; amine; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.</td></tr><tr><th>Pharmacodynamics</th><td>Ipratropium bromide, a synthetic ammonium compound structurally similar to atropine, is used as a bronchodilator in the management of cholinergic-mediated bronchospasm associated with chronic obstructive pulmonary disease and in the treatment of rhinorrhea associated with the common cold or with allergic or nonallergic seasonal rhinitis.</td></tr><tr><th>Mechanism of action</th><td>Ipratropium bromide is an anticholinergic agent. It blocks muscarinic cholinergic receptors, without specificity for subtypes, resulting in a decrease in the formation of cyclic guanosine monophosphate (cGMP). Most likely due to actions of cGMP on intracellular calcium, this results in decreased contractility of smooth muscle.</td></tr><tr><th>Absorption</th><td>Inhalation (local)-minimal; Nasal-rapid and minimal</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>4.6 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>Minimally (0 to 9% in vitro) bound to plasma albumin and &#945;1-acid glycoproteins</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Partially metabolized to at least 8 metabolites formed primarily via hydrolysis and conjugation. The main metabolites are N-isopropylnortropium methobromide, which is formed by enzymatic hydrolysis of the ester; &#945;-phenylacrylic acid-N-isopropylnortropine-ester methobromide, which is formed by enzymatic loss of a water; and phenylacetic acid-N-isopropylnortropine-ester methobromide, which is formed by enzymatic loss of a CH<sub>3</sub>OH-group. These metabolites appear to be inactive. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Ipratropium bromide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00945">N-isopropylnortropium methobromide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/966">Details</a></td></tr><tr><td>Ipratropium bromide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00987">Phenylacetic acid-N-isopropylnortropine-ester methobromide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1010">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Primarily eliminated renally via active secretion. </td></tr><tr><th>Half life</th><td>2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &#945;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &#946;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults. </td></tr><tr><th>Clearance</th><td><ul>
	<li>2.3 L/min (total clearance of active ingredient)</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=1001mg/kg (orally in mice)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.9425</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8883</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6619</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5085</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8489</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5964</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.6651</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7214</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7637</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6657</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8412</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9118</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8915</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8783</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9396</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9528</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7112
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8979
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.5154
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7983 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9596
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5879
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Boehringer ingelheim pharmaceuticals inc</li>
<li>Actavis mid atlantic llc</li>
<li>Bausch and lomb pharmaceuticals inc</li>
<li>Cobalt laboratories inc</li>
<li>Dey lp</li>
<li>Holopack international corp</li>
<li>Landela pharmaceutical</li>
<li>Nephron corp</li>
<li>Novex pharma</li>
<li>Pharmascience inc</li>
<li>Roxane laboratories inc</li>
<li>Teva parenteral medicines inc</li>
<li>Bausch and lomb inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.3m.com">3M Health Care</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Automatic Liquid Packaging Inc.</li>
<li><a href="http://www.bausch.com">Bausch &amp; Lomb Inc.</a></li>
<li><a href="http://www.boehringer-ingelheim.com">Boehringer Ingelheim Ltd.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.catalent.com">Catalent Pharma Solutions</a></li>
<li><a href="http://www.cipla.com">Cipla Ltd.</a></li>
<li><a href="http://www.cobaltpharma.com">Cobalt Pharmaceuticals Inc.</a></li>
<li><a href="http://www.dey.com">Dey Pharma LP</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Eon Labs</li>
<li>Holopack International Corp.</li>
<li>Ivax Pharmaceuticals</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nephronpharm.com">Nephron Pharmaceuticals Corp.</a></li>
<li>Novex Pharma</li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.rxelite.com">Rx Elite</a></li>
<li><a href="http://www.sifavitor.com">Sifavitor Srl</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Aerosol, metered</td><td>Nasal</td><td>21 mcg, 42 mcg</td></tr><tr><td>Solution</td><td>Respiratory (inhalation)</td><td>0.0125%, 0.02%, 0.025%</td></tr><tr><td>Spray, metered</td><td>Nasal</td><td>17 mcg, 20 mcg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Ipratropium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.</td></tr><tr><td><a href="/drugs/DB00662">Trimethobenzamide</a></td><td>Trimethobenzamide and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>Triprolidine and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00209">Trospium</a></td><td>Trospium and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>